CCCC C4 Therapeutics Inc.

C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; and BRAF V600E to treat melanoma, non-small cell lung cancer, colorectal cancer, and other solid malignancies, as well as RET to treat lung cancer, sporadic medullary thyroid cancers, and other solid malignancies. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffman-La Roche Ltd.; Biogen, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Date	Price Target	Rating	Analyst
12/19/2024	$8.00 → $12.00	Equal Weight → Overweight	Wells Fargo
11/18/2024	$4.00	Equal-Weight	Stephens
1/29/2024	$6.00	Underweight → Neutral	JP Morgan
12/13/2023	$2.00 → $12.00	Hold → Buy	Stifel
2/24/2023	$12.00 → $10.00	Underperform → Neutral	Credit Suisse
2/24/2023	$15.00 → $5.00	Neutral → Underweight	JP Morgan
11/4/2022	$22.00 → $15.00	Overweight → Neutral	JP Morgan
10/11/2022	$6.00	Underweight	Morgan Stanley
4/28/2022	$10.00	Underperform	Credit Suisse
4/11/2022	$46.00 → $15.00	Buy → Neutral	BofA Securities

C4 Therapeutics Inc.

Peers

Recent Analyst Ratings for C4 Therapeutics Inc.

C4 Therapeutics Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Grogan Donna Roy was granted 9,581 shares, increasing direct ownership by 29% to 42,280 units (SEC Form 4)

Director Anderson Kenneth Carl was granted 7,841 shares, increasing direct ownership by 7% to 127,609 units (SEC Form 4)

President & CEO Hirsch Andrew covered exercise/tax liability with 22,217 shares and was granted 223,500 shares, increasing direct ownership by 91% to 423,145 units (SEC Form 4)

Chief Legal Officer Siegel Jolie covered exercise/tax liability with 5,049 shares and was granted 56,500 shares, increasing direct ownership by 91% to 107,939 units (SEC Form 4)

Chief Business Officer Boyle Scott N covered exercise/tax liability with 4,103 shares, was granted 56,500 shares and sold $3,651 worth of shares (1,159 units at $3.15), increasing direct ownership by 91% to 107,805 units (SEC Form 4)

Chief Accounting Officer Mossler Mark covered exercise/tax liability with 1,586 shares, decreasing direct ownership by 8% to 18,204 units (SEC Form 4)

Chief People Officer Schick Kelly was granted 56,500 shares and covered exercise/tax liability with 4,103 shares, increasing direct ownership by 93% to 108,885 units (SEC Form 4)

Chief Financial Officer Adams Kendra covered exercise/tax liability with 6,422 shares and was granted 87,100 shares, increasing direct ownership by 96% to 165,117 units (SEC Form 4)

Chief Scientific Officer Mahaney Paige was granted 28,200 shares, increasing direct ownership by 37% to 105,000 units (SEC Form 4)

Chief Medical Officer Reyno Leonard was granted 87,100 shares and covered exercise/tax liability with 5,145 shares, increasing direct ownership by 89% to 173,764 units (SEC Form 4)